

Abstract (Basic): JP 61000017

Carcinoma metastasis inhibiting mucopolysaccharide drug, which is hyaluronic acid (HA) or crosslinked HA or their salt, as active ingredient.

M.W. of HA used is several thousand-several million. Crosslinked HA is crosslinked by multifunctional epoxy cpd. to HA or its salt, while crosslinked number is more than 5 against 1000-repeated disaccharide of HA. As multifunctional epoxy cpd., halomethyloxirane cpd. or bisepoxy cpd. eq. epichlorohydrin is used. Crosslinked HA has resistance to hyaluronidase.

More than 1.0% or HA is dissolved in alkaline aq. soln. and pref. more than 50% of H₂O sol. org. solvent. eq. alcohol, acetone, dioxane, against total soln. is added. Pref. pH is 12-14. Then emulfifunctional epoxy cpd. is added and reacted at 10-60 deg.C, pref. at 20-40 deg.C for 24-2 hrs.. Crosslinking ratio of crosslinked HA or its salt is regulated by changing mol ratio of HA or its salt and multifunctional epoxy cpd.. Pref. HA used in this invention has intrinsic viscosity 0.2-30, m.w. 4000-2000000. This drug is used as several dosage forms. Clinical dose for adult is normally, as HA or crosslinked HA, 25mg-5 g/day (p.o.) and 10 mg-2.5 g/l dose (inj).

ADVANTAGE - Drug has no side effects as other anticancer drugs and has analgesic and tissue restoration effect. @ (13pp Dwg.No.0/0) @